Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification and validation of GPD1 as an essential cancer stem cell specific target in glioblastoma

ABSTRACT: Identification and validation of GPD1 as an essential cancer stem cell specific target in glioblastoma

PROVIDER: PRJNA434706 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6751080.fastq.gz	Fastqsanger.gz
	SRR6751100.fastq.gz	Fastqsanger.gz
	SRR6751110.fastq.gz	Fastqsanger.gz
	SRR6751081.fastq.gz	Fastqsanger.gz
	SRR6751101.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 36

Similar Datasets

Identification and validation of GPD1 as an essential cancer stem cell specific target in glioblastoma (RNA-seq: Gpd1 KO)

Project description:Cancer stem cells (CSCs) are attractive targets for cancer therapy, however, little is known about how to target CSCs without affecting the normal stem cell population. Here we report the ribosome-profiling analysis of mouse neural stem cells and brain tumour stem cells (BTSCs), which leads to the identification of glycerol-3-phosphate dehydrogenase 1 (GPD1) as a CSC- specific determinant. We confirmed that GPD1 is expressed in BTSCs but not in neural stem cells. Intriguingly, expression of GPD1 is only found in the infiltrating dormant BTSCs in vivo and these cells start to divide and drive tumour relapse after chemotherapy. Most importantly, inhibition of GPD1 expression in tumour-bearing mice leads to prolonged survival. Further analysis shows that loss of GPD1 results in widespread changes in important pathways affecting BTSC maintenance. Human patient data analysis suggests that GPD1 is expressed in the dormant infiltrating tumour cells in human glioblastoma and the expression level is associated with a worse prognosis. This study provides an attractive therapeutic target for treating brain tumours and a novel aspect of regulation of CSC dormancy.

2019-07-15 | GSE110868 | GEO

Identification and validation of GPD1 as an essential cancer stem cell specific target in glioblastoma (RNA-seq: Gpd1 KO)

Project description:Identification and validation of GPD1 as an essential cancer stem cell specific target in glioblastoma (RNA-seq: Gpd1 KO)

| PRJNA434718 | ENA

Identification and validation of GPD1 as an essential cancer stem cell specific target in glioblastoma (Ribosome profiling)

2019-07-15 | GSE110866 | GEO

Identification and validation of GPD1 as an essential cancer stem cell specific target in glioblastoma (RNA-seq: NSC vs BTSC)

2019-07-15 | GSE110867 | GEO

Identification and validation of GPD1 as an essential cancer stem cell specific target in glioblastoma (Ribosome profiling)

Project description:Identification and validation of GPD1 as an essential cancer stem cell specific target in glioblastoma (Ribosome profiling)

| PRJNA434716 | ENA

Identification and validation of GPD1 as an essential cancer stem cell specific target in glioblastoma (RNA-seq: NSC vs BTSC)

Project description:Identification and validation of GPD1 as an essential cancer stem cell specific target in glioblastoma (RNA-seq: NSC vs BTSC)

| PRJNA434717 | ENA

Identification and validation of GPD1 as an essential cancer stem cell specific target in glioblastoma

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-07-15 | GSE110869 | GEO

The FFPE samples of the primary vs. recurrent glioblastoma validation cohort

Project description:The FFPE samples of the primary vs. recurrent glioblastoma validation cohort

2022-08-08 | PXD035867 |

Validation of human microRNA target pathways enables evaluation of target prediction tools

Project description:Validation of human microRNA target pathways enables evaluation of target prediction tools

| PRJNA557590 | ENA

GPD1 enhances the anti-cancer effects of metformin by synergistically increasing total cellular glycerol-3-phosphate

Project description:GPD1 overexpression enhances the anti-cancer effect of metformin through synergistic inhibition of mitochondrial function, thereby providing new insight into metformin-mediated cancer therapy.

2020-03-15 | GSE146982 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data